The efficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy.

Abstract

Recent studies demonstrate that, treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor blockers may decrease left ventricular hypertrophy (LVH) in hypertensive patients. We wanted to assess the efficacy of valsartan on echocardiographic variables of LVH in 30 mild to moderate hypertensive patients. Valsartan was found effective in controlling hypertension, also echocardiographic indices of LVH such as interventricular septum and posterior wall thickness were reduced and left ventricular mass decreased significantly. Thus valsartan favorably influences cardiac structure in hypertensive patients.

• Authors: Haşim Mutlu, Hakan Ozhan, Bariş Okçün, Ertugrul Okuyan, Zerrin Yigit, Cennet Erbaş, M Serdar Küçükoglu, Nazmi Gültekin, Sinan Uner, Serap Erdine, Ozen Güven
• Journal: Blood pressure (Blood Press) Vol. 11 Issue 1 Pg. 53-5 ( 2002) ISSN: 0803-7051 [Print] England
• PMID: 11926352 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Angiotensin-Converting Enzyme Inhibitors
• Tetrazoles
• Valsartan
• Valine

Topics

• Adult
• Angiotensin-Converting Enzyme Inhibitors (administration & dosage, pharmacology)
• Cohort Studies
• Hemodynamics (drug effects)
• Humans
• Hypertension (drug therapy, pathology)
• Hypertrophy, Left Ventricular (diagnostic imaging, drug therapy)
• Middle Aged
• Tetrazoles (administration & dosage, pharmacology)
• Therapeutic Equivalency
• Treatment Outcome
• Ultrasonography
• Valine (administration & dosage, analogs & derivatives, pharmacology)
• Valsartan